Skip to main content

ALERT: KPBS 89.5FM is undergoing scheduled upgrade work which may result in a temporary signal outage. Click here to listen on our radio stream.

LATEST UPDATES: Tracking COVID-19 | Vaccines | Racial Justice

San Diego Scientist Compares Obesity Drugs, Finds No ‘Magic Bullets’


Here's what UC San Diego's Siddharth Singh said: "The magnitude of weight loss across all these medicines was not very impressive."

After comparing five FDA-approved obesity drugs, a San Diego scientist says none of them are highly effective, though some lead to more weight loss than others.

"The magnitude of weight loss across all these medicines was not very impressive," said Siddharth Singh, assistant professor of medicine at UC San Diego and senior author on a new study published in JAMA on Tuesday analyzing the drugs.

"Patients need to be aware that these are not magic bullets that will result in a lot of weight loss," he said.

For the study, Singh and his colleagues drew on data from clinical trials conducted in the run-up to approval for each drug. In total, nearly 30,000 patients participated in these trials. Singh said this is the first study comparing all five drugs.

Phentermine-topiramate, sold under the brand name Qsymia, produced the most weight loss after one year. On average, patients taking the drug lost 19.4 pounds.

The second most effective drug was liraglutide, known as Saxenda. It was associated with 11.7 pounds of weight loss on average.

Lower down the list were two drugs made by San Diego companies. Naltrexone-bupropion (developed by Orexigen Therapeutics and known as Contrave) helped patients shed 11 pounds on average. And lorcaserin (made by Arena Pharmaceuticals and known as Belviq) led to an average of 7.1 pounds of weight loss.

At the bottom of the list, orlistat — sold over the counter as Alli — produced only 5.4 pounds of weight loss on average.

Singh said that while their effects are modest, all of these drugs were associated with more weight loss than a placebo. He said losing even just 5 percent to 10 percent of overall body weight can bring health benefits to obese patients.

"At the same time, medications alone are unlikely to ever be successful in keeping off weight," Singh said. "At the end of the day, it's going to be diet and exercise that is going to help maintain that weight loss."

Many patients dropped out of the trials, anywhere from 30 percent to 45 percent. They often stopped taking the drugs because they weren’t seeing results or were experiencing negative side effects.

Common side effects from these drugs include nausea, vomiting and other gastrointestinal issues, Singh said. Naltrexone-bupropion and liraglutide had the highest odds of producing negative side effects.

Singh said doctors shouldn't choose which drugs to prescribe based solely on this ranking, because certain drugs can cause specific side effects for some individuals. For instance, naltrexone-bupropion leads to psychiatric issues in patients with opiate and alcohol addictions.

"There is no one size fits all," Singh said.

Over a third of American adults are obese, but Singh said these five drugs are rarely prescribed. Many of them are fairly new, and they may not be covered by health insurance.

Singh hopes the study's findings can better inform doctors and health providers about which drugs make sense for which patients. He also hopes to see more long-term data on the safety and effectiveness of each drug.


San Diego News Now podcast branding

San Diego news; when you want it, where you want it. Get local stories on politics, education, health, environment, the border and more. New episodes are ready weekday mornings. Hosted by Anica Colbert and produced by KPBS, San Diego and the Imperial County's NPR and PBS station.

  • Need help keeping up with the news that matters most? Get the day's top news — ranging from local to international — straight to your inbox each weekday morning.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curious San Diego banner

Want more KPBS news?
Find us on Twitter and Facebook, or sign up for our newsletters.

To view PDF documents, Download Acrobat Reader.